Rua Bioscience (RUA) H2 2024 earnings summary

Executive summary

• Achieved first revenues in Australia and expanded distribution channels in key global markets, including Germany and the UK.

• Extended major distribution agreements and launched new products in Germany and New Zealand.

• Focused on a capital-light, export-led strategy centered on genetics and distribution.

• Expanded social impact and sustainability initiatives, including scholarships and a Compassionate Access Programme.

Financial highlights

• Revenue from customers was $86k, with total revenue and other income at $322k, down from $6.53m in FY23 due to a prior year non-cash gain.

• Loss before tax was $13.7m (FY23: $6.0m), primarily due to one-off impairments to goodwill, supplier contracts, and other assets.

• Cash and investments at year-end totaled $895k, with net assets of $6.8m.

• Significant impairments of $9.23m recorded during the year.

Outlook and guidance

• Entering a new revenue growth phase, with product launches planned for the UK and further expansion in Germany and Australia.

• Focus on achieving sustainable revenue and leveraging partnerships in maturing international markets.

• Proceeds from the sale of the Gisborne manufacturing facility and additional capital raising expected to support operations.